NANETS Treatment Guidelines Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas

被引:406
作者
Kulke, Matthew H. [1 ]
Anthony, Lowell B. [2 ]
Bushnell, David L. [3 ]
de Herder, Wouter W. [4 ]
Goldsmith, Stanley J. [5 ]
Klimstra, David S. [6 ]
Marx, Stephen J. [7 ]
Pasieka, Janice L. [8 ]
Pommier, Rodney F. [9 ]
Yao, James C. [10 ]
Jensen, Robert T. [11 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Louisiana State Univ, Div Hematol Oncol, Hlth Sci Ctr, New Orleans, LA USA
[3] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA
[4] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands
[5] Cornell Univ, Div Nucl Med, Dept Radiol, New York Presbyterian Hosp,Weill Med Coll, Ithaca, NY 14853 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[7] NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA
[8] Univ Calgary, Dept Surg, Calgary, AB, Canada
[9] Oregon Hlth & Sci Univ, Div Surg Oncol, Dept Gen Surg, Portland, OR 97201 USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[11] NIH, Digest Dis Branch, Bethesda, MD 20892 USA
关键词
islet cell; gastric; carcinoid; guidelines; review; ZOLLINGER-ELLISON-SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; SOMATOSTATIN-RECEPTOR SCINTIGRAPHY; GASTRIC CARCINOID-TUMORS; PROTON-PUMP INHIBITORS; ISLET-CELL-CARCINOMA; DUODX AFFECT RATE; PHASE-II TRIAL; LONG-TERM; LIVER METASTASES;
D O I
10.1097/MPA.0b013e3181ebb168
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2 major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the classification and management of patients with these tumor subtypes. We provide an overview of well-differentiated NETs of the stomach and pancreas and describe consensus guidelines for the treatment of patients with these malignancies.
引用
收藏
页码:735 / 752
页数:18
相关论文
共 187 条
[51]   Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects [J].
Gola M. ;
Doga M. ;
Bonadonna S. ;
Mazziotti G. ;
Vescovi P.P. ;
Giustina A. .
Pituitary, 2006, 9 (3) :221-229
[52]   False-Positive Secretin Stimulation Test for Gastrinoma Associated With the Use of Proton Pump Inhibitor Therapy [J].
Goldman, Joshua A. ;
Blanton, Wanda P. ;
Hay, David W. ;
Wolfe, M. Michael .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (05) :600-602
[53]   DIAZOXIDE IN THE MANAGEMENT OF PATIENTS WITH INSULINOMA [J].
GOODE, PN ;
FARNDON, JR ;
ANDERSON, J ;
JOHNSTON, IDA ;
MORTE, JA .
WORLD JOURNAL OF SURGERY, 1986, 10 (04) :586-592
[54]   Insulinoma [J].
Grant, CS .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2005, 19 (05) :783-798
[55]  
GUILLAUSSEAU PJ, 1995, ENDOCRINE TUMORS PAN, P183
[56]  
Gullo L, 2003, AM J GASTROENTEROL, V98, P2435
[57]   Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors - Variables affecting response rates and survival [J].
Gupta, S ;
Johnson, MM ;
Murthy, R ;
Ahrar, K ;
Wallace, MJ ;
Madoff, DC ;
McRae, SE ;
Hicks, ME ;
Rao, S ;
Vauthey, JN ;
Ajani, JA ;
Yao, JC .
CANCER, 2005, 104 (08) :1590-1602
[58]   Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The MD Anderson experience [J].
Gupta, S ;
Yao, JC ;
Ahrar, K ;
Wallace, MJ ;
Morello, FA ;
Madoff, DC ;
Murthy, R ;
Hicks, ME ;
Ajani, JA .
CANCER JOURNAL, 2003, 9 (04) :261-267
[59]   Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study [J].
Hainsworth, John D. ;
Spigel, David R. ;
Litchy, Sharlene ;
Greco, F. Anthony .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3548-3554
[60]   Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1 [J].
Hellman, P ;
Hennings, J ;
Åkerström, G ;
Skogseid, B .
BRITISH JOURNAL OF SURGERY, 2005, 92 (12) :1508-1512